Vertex Pharmaceuticals (VRTX) Other Accumulated Expenses (2009 - 2026)

Vertex Pharmaceuticals has reported Other Accumulated Expenses for 18 years, with the latest figure at $407.1 million in Q1 2026.

• For the quarter ending Q1 2026, Other Accumulated Expenses rose 5.36% year-over-year to $407.1 million; the trailing twelve-month figure through Mar 2026 stood at $407.1 million (up 5.36% YoY), and the FY2025 full-year result was $428.3 million, up 17.99% from the prior year.
• Other Accumulated Expenses for Q1 2026 stood at $407.1 million, down from $428.3 million in the prior quarter.
• The five-year high for Other Accumulated Expenses was $648.6 million in Q1 2024, with the low at $218.0 million in Q3 2022.
• Average Other Accumulated Expenses over 5 years is $376.6 million, with a median of $377.0 million recorded in 2023.
• Year-over-year, Other Accumulated Expenses surged 72.04% in 2024 and slumped 40.43% in 2025.
• Tracing VRTX's Other Accumulated Expenses over 5 years: stood at $311.5 million in 2022, then surged by 69.25% to $527.2 million in 2023, then slumped by 31.15% to $363.0 million in 2024, then grew by 17.99% to $428.3 million in 2025, then slipped by 4.95% to $407.1 million in 2026.
• The last three Other Accumulated Expenses figures came in at $407.1 million (Q1 2026), $428.3 million (Q4 2025), and $441.5 million (Q3 2025), per Business Quant data.

Peer Comparison